These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12742465)

  • 1. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience.
    Kahan BD; Knight R; Schoenberg L; Pobielski J; Kerman RH; Mahalati K; Yakupoglu Y; Aki FT; Katz S; Van Buren CT
    Transplant Proc; 2003 May; 35(3 Suppl):25S-34S. PubMed ID: 12742465
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus antirejection therapy for renal transplantation with cyclosporine-based immunosuppression: case reports.
    Tsai MK; Hu RH; Lee PH
    Transplant Proc; 2003 Feb; 35(1):219-20. PubMed ID: 12591371
    [No Abstract]   [Full Text] [Related]  

  • 3. Sirolimus rescue therapy for refractory rejection in renal transplant recipients.
    Hong JC; Kahan BD
    Transplant Proc; 2001; 33(1-2):1033. PubMed ID: 11267178
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation.
    Vilalta R; Vila A; Nieto J; Callís L
    Transplant Proc; 2003 Mar; 35(2):703-4. PubMed ID: 12644102
    [No Abstract]   [Full Text] [Related]  

  • 5. A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function in renal transplantation.
    Hong JC; Kahan BD
    Transplant Proc; 2001; 33(1-2):1271-2. PubMed ID: 11267288
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 7. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.
    Machado PG; Garcia C; Felipe CR; Garcia R; Franco M; Delcelo R; Silva HT; Medina JO
    Transplant Proc; 2001; 33(1-2):1074-5. PubMed ID: 11267196
    [No Abstract]   [Full Text] [Related]  

  • 10. Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody.
    Kerman RH; Katz SM; Van Buren CT; Garcia C; Kahan BD
    Transplant Proc; 2001; 33(1-2):401. PubMed ID: 11266881
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of sirolimus: The University of Texas-Houston experience.
    Kahan BD; Stepkowski SM; Napoli KL; Katz SM; Knight RJ; Van Buren C
    Clin Transpl; 2000; ():145-58. PubMed ID: 11512308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid withdrawal in renal transplant recipients.
    Oppenheimer F
    Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience with sirolimus for calcineurin minimization/elimination in pancreas-after-kidney transplantation.
    Gautam A; Morrissey PE; Gohh R; Yango A; Monaco AP
    Transplant Proc; 2005 Oct; 37(8):3542-3. PubMed ID: 16298654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Rapamune replace cyclosporine? No significant difference in rejection rate after six months; long-term studies needed.
    Nephrol News Issues; 2000 Aug; 14(9):S9-10. PubMed ID: 11933435
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy.
    Mahalati K; Kahan BD
    Transplant Proc; 2001; 33(7-8):3232-3. PubMed ID: 11750385
    [No Abstract]   [Full Text] [Related]  

  • 17. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience.
    Wiseman AC; Kam I; Christians U; Jani A; Bak T; Wachs M; Chan L
    Transplant Proc; 2003 May; 35(3 Suppl):122S-124S. PubMed ID: 12742482
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of everolimus in pediatric kidney transplantation.
    Tönshoff B
    Pediatr Transplant; 2014 Jun; 18(4):323-4. PubMed ID: 24802339
    [No Abstract]   [Full Text] [Related]  

  • 19. Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
    Ponticelli C
    Transplant Proc; 2001; 33(1-2):1031-2. PubMed ID: 11267177
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapamycin reduces rejection in heart transplant recipients.
    Radovancevic B; El-Sabrout R; Thomas C; Radovancevic R; Frazier OH; Van Buren C
    Transplant Proc; 2001; 33(7-8):3221-2. PubMed ID: 11750381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.